Developer docs
API playgroundTry for free, no card

Search company profiles

OncoC4

Full company profile

uuid00003co

Namestring
OncoC4
Legal namestring
OncoC4, Inc.
Websiteurl
oncoc4.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

OncoC4 is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Rockville, Maryland, that develops first-in-class and best-in-class immunotherapy candidates for hard-to-treat cancers and neurodegenerative diseases. The company's scientific approach targets innate and adaptive immune checkpoints — CTLA-4, PD-1/VEGF, CD24, and Siglec — across multiple antibody modalities including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. Its lead asset, gotistobart (BNT316/ONC-392), is a pH-sensitive anti-CTLA-4 antibody co-developed with BioNTech that preserves CTLA-4 recycling while preferentially depleting immunosuppressive tumor T cells; it is in Phase 3 development (PRESERVE-003) for second-line squamous non-small cell lung cancer, with reported 54% reduction in death risk versus docetaxel. The pipeline also includes ONC-841, now in Phase 1/2 for Alzheimer's disease in China, plus earlier-stage PD-1/VEGF, CD24, and Siglec programs. The company operates a lean 11-50 person team with wholly-owned subsidiaries in China (Nanjing, Guangzhou, Beijing) and Australia (Brisbane) to support global clinical execution.

The business model is a clinical development and partnership model typical of pre-commercial biotech. OncoC4 does not currently generate commercial revenue and identifies future income as coming from potential product sales upon regulatory approval or one-time licensing arrangements. The company relies on strategic partnerships for co-development and eventual commercialization — notably with BioNTech for gotistobart and with Bristol Myers Squibb for pumitamig — while funding operations through equity financings, including a nearly $50 million Series B round in October 2025 led by GBA Fund. Customer segments are therapeutic indications rather than paying customers: oncology (immunotherapy-resistant NSCLC, platinum-resistant ovarian cancer, squamous NSCLC) is the primary segment, with neurodegenerative disease (Alzheimer's) as a secondary segment. Value proposition centers on differentiated antibody engineering that may improve efficacy and reduce immune-related adverse events relative to conventional checkpoint inhibitors, supported by FDA Orphan Drug Designation and Phase 3 survival data.

Short descriptiontext

OncoC4 is a clinical-stage biopharmaceutical company developing novel immunotherapy antibodies targeting CTLA-4, PD-1/VEGF, CD24, and Siglec pathways for hard-to-treat cancers and neurodegenerative diseases, partnered with BioNTech and Bristol Myers Squibb.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy, monoclonal antibodies, immune checkpoint inhibitors, clinical-stage biopharmaceutical, antibody therapeutics
Industry3 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Immunotherapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pipeline Development and Potential Commercialization
TypeOne Time License
Description

As a clinical-stage biotechnology company, OncoC4 is developing cancer and neurodegenerative disease therapies with multiple candidates in clinical trials. Revenue would be generated through potential future product sales upon regulatory approval.

oncoc4.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

OncoC4 discovers and develops novel biological therapeutics targeting innate and adaptive immune checkpoints—specifically CTLA-4, PD-1/VEGF, CD24, and Siglec pathways—for hard-to-treat cancers and neurodegenerative diseases such as Alzheimer's. The company leverages proprietary pH-sensitive antibody engineering and multiple modalities including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. Its lead clinical candidate, gotistobart (ONC-392/BNT316), is a pH-sensitive anti-CTLA-4 antibody co-developed with BioNTech, with a second candidate ONC-841 advancing in oncology and Alzheimer's disease indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Gotistobart demonstrated 54% reduction in death risk (HR 0.46) versus standard chemotherapy in Phase 3 trial for squamous NSCLC
+1 more record
Product overview1 text field

OncoC4 is a clinical-stage biopharmaceutical company developing first-in-class and best-in-class medicines for hard-to-treat cancer and Alzheimer's disease. The company's product portfolio centers on its lead candidate Gotistobart (ONC-392/BNT316), a pH-sensitive anti-CTLA-4 antibody developed in partnership with BioNTech, currently in late-stage clinical trials for lung and ovarian cancers. Beyond Gotistobart, OncoC4 is advancing ONC-841 for both solid tumors and Alzheimer's disease. The company's therapeutic approach leverages a diverse array of modalities including monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs), targeting immune checkpoints including CTLA-4, PD-1/VEGF, CD24, and Siglecs.

Product and service2 records
1Gotistobart (ONC-392/BNT316)
CategoryCancer Immunotherapy - Lead Clinical Candidate
Description

A pH-sensitive anti-CTLA-4 monoclonal antibody designed to preserve CTLA-4 recycling while preferentially depleting immunosuppressive T cells within tumors. Co-developed with BioNTech for treatment of immunotherapy-resistant non-small cell lung cancer and other advanced tumors; demonstrated 54% reduction in death risk (HR 0.46) versus standard chemotherapy in Phase 3 squamous NSCLC.

2ONC-841
CategoryNeurodegenerative and Oncology Therapy Candidate
Description

A therapeutic candidate being developed for solid tumors and Alzheimer's disease, currently in Phase 1/2 clinical trial for Alzheimer's disease following prior development for oncology indications. The candidate leverages Siglec pathway targeting to restore microglial function.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1BioNTech SE
Strategic tierCoreTypeStrategic or Co-development Partner
Description

BioNTech and OncoC4 co-developed gotistobart (BNT316/ONC-392), a pH-sensitive anti-CTLA-4 antibody demonstrating sustained anti-tumor activity and clinically relevant overall survival rates in platinum-resistant ovarian cancer. BioNTech presents clinical data at major conferences including ASCO 2026. Partnership advancing multiple late-stage clinical trials.

globenewswire.com
2Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for development of pumitamig, an immunomodulator candidate. BioNTech highlighted pumitamig data from ROSETTA Lung-02 trial showing encouraging anti-tumor activity in first-line non-small cell lung cancer. Multiple global Phase 3 studies ongoing.

biospace.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage immuno-oncology company developing novel checkpoint-based therapeutics using a computational discovery platform. Comparable to OncoC4 in stage, size, and focus on next-generation immune checkpoint targets for solid tumors.

TypeDirect peer
Description

Clinical-stage biotech developing conditionally activated immuno-oncology therapeutics, including PREDATOR platform-based INDUKINE molecules. Similar size, clinical-stage profile, and IO focus to OncoC4.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing bifunctional fusion proteins and bispecifics targeting TNF superfamily and immune checkpoints. Direct overlap with OncoC4's BsAb modality and checkpoint pipeline.

4Surface Oncology
TypeDirect peer
Description

Clinical-stage immuno-oncology biotech focused on next-generation antibodies targeting innate and adaptive immune checkpoints. Highly comparable in target space (PVRIG, IL-27) and stage to OncoC4.

5Pionyr Immunotherapeutics
TypeDirect peer
Description

Clinical-stage immuno-oncology company developing myeloid-targeting antibodies for solid tumors. Overlaps with OncoC4's innate immune checkpoint approach (e.g., Siglec, CD24 targeting) and clinical-stage profile.

6Bristol Myers Squibb
TypeBroad incumbent
Description

Global pharma with the leading approved anti-CTLA-4 (ipilimumab/Yervoy) and PD-1 (Opdivo) franchises. OncoC4's BMS partnership for pumitamig plus its CTLA-4 ambitions place BMS as both partner and principal incumbent competitor.

TypeBroad incumbent
Description

Owns Keytruda (pembrolizumab), the dominant PD-1 checkpoint inhibitor against which OncoC4's PD-1/VEGF program will compete. Represents the standard-of-care benchmark for OncoC4's IO development.

TypeBroad incumbent
Description

Major IO player with Tecentriq (anti-PD-L1) and broad bispecific antibody pipeline. Comparable commercial and development scope to OncoC4's IO ambitions across multiple checkpoint targets.

TypeBroad incumbent
Description

Owns Imfinzi (anti-PD-L1) and tremelimumab (anti-CTLA-4), the most direct approved competitor to gotistobart. Comparable dual-checkpoint strategy (PD-1/VEGF parallels Imfinzi+tremelimumab combinations).

TypeRegional player
Description

Leading Chinese biopharma with marketed PD-1 inhibitor (sintilimab) and broad oncology biologics pipeline including bispecifics. Comparable to OncoC4 in bispecific antibody development and Chinese clinical footprint via OncoC4's Nanjing/Guangzhou/Beijing subsidiaries.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OncoC4

Cancer Immunotherapyoncoc4.com

OncoC4 is a clinical-stage biopharmaceutical company developing novel immunotherapy antibodies targeting CTLA-4, PD-1/VEGF, CD24, and Siglec pathways for hard-to-treat cancers and neurodegenerative diseases, partnered with BioNTech and Bristol Myers Squibb.

What OncoC4 does

OncoC4 is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Rockville, Maryland, that develops first-in-class and best-in-class immunotherapy candidates for hard-to-treat cancers and neurodegenerative diseases. The company's scientific approach targets innate and adaptive immune checkpoints — CTLA-4, PD-1/VEGF, CD24, and Siglec — across multiple antibody modalities including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. Its lead asset, gotistobart (BNT316/ONC-392), is a pH-sensitive anti-CTLA-4 antibody co-developed with BioNTech that preserves CTLA-4 recycling while preferentially depleting immunosuppressive tumor T cells; it is in Phase 3 development (PRESERVE-003) for second-line squamous non-small cell lung cancer, with reported 54% reduction in death risk versus docetaxel. The pipeline also includes ONC-841, now in Phase 1/2 for Alzheimer's disease in China, plus earlier-stage PD-1/VEGF, CD24, and Siglec programs. The company operates a lean 11-50 person team with wholly-owned subsidiaries in China (Nanjing, Guangzhou, Beijing) and Australia (Brisbane) to support global clinical execution.

The business model is a clinical development and partnership model typical of pre-commercial biotech. OncoC4 does not currently generate commercial revenue and identifies future income as coming from potential product sales upon regulatory approval or one-time licensing arrangements. The company relies on strategic partnerships for co-development and eventual commercialization — notably with BioNTech for gotistobart and with Bristol Myers Squibb for pumitamig — while funding operations through equity financings, including a nearly $50 million Series B round in October 2025 led by GBA Fund. Customer segments are therapeutic indications rather than paying customers: oncology (immunotherapy-resistant NSCLC, platinum-resistant ovarian cancer, squamous NSCLC) is the primary segment, with neurodegenerative disease (Alzheimer's) as a secondary segment. Value proposition centers on differentiated antibody engineering that may improve efficacy and reduce immune-related adverse events relative to conventional checkpoint inhibitors, supported by FDA Orphan Drug Designation and Phase 3 survival data.

OncoC4 firmographics

Firmographics
Name
OncoC4
Legal name
OncoC4, Inc.
Website
https://oncoc4.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
OncoC4 is a clinical-stage biopharmaceutical company developing novel immunotherapy antibodies targeting CTLA-4, PD-1/VEGF, CD24, and Siglec pathways for hard-to-treat cancers and neurodegenerative diseases, partnered with BioNTech and Bristol Myers Squibb.
Ownership category
akta.pro rank

OncoC4 industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cancer immunotherapy
  • Monoclonal antibodies
  • Immune checkpoint inhibitors
  • Clinical-stage biopharmaceutical
  • Antibody therapeutics

Where OncoC4 is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices5 records

Markets served

OncoC4 business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pipeline Development and Potential Commercialization: As a clinical-stage biotechnology company, OncoC4 is developing cancer and neurodegenerative disease therapies with multiple candidates in clinical trials. Revenue would be generated through potential future product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

OncoC4 product offering

Product offering

Core offering

OncoC4 discovers and develops novel biological therapeutics targeting innate and adaptive immune checkpoints—specifically CTLA-4, PD-1/VEGF, CD24, and Siglec pathways—for hard-to-treat cancers and neurodegenerative diseases such as Alzheimer's. The company leverages proprietary pH-sensitive antibody engineering and multiple modalities including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. Its lead clinical candidate, gotistobart (ONC-392/BNT316), is a pH-sensitive anti-CTLA-4 antibody co-developed with BioNTech, with a second candidate ONC-841 advancing in oncology and Alzheimer's disease indications.

Product overview

OncoC4 is a clinical-stage biopharmaceutical company developing first-in-class and best-in-class medicines for hard-to-treat cancer and Alzheimer's disease. The company's product portfolio centers on its lead candidate Gotistobart (ONC-392/BNT316), a pH-sensitive anti-CTLA-4 antibody developed in partnership with BioNTech, currently in late-stage clinical trials for lung and ovarian cancers. Beyond Gotistobart, OncoC4 is advancing ONC-841 for both solid tumors and Alzheimer's disease. The company's therapeutic approach leverages a diverse array of modalities including monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs), targeting immune checkpoints including CTLA-4, PD-1/VEGF, CD24, and Siglecs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Gotistobart (ONC-392/BNT316) A pH-sensitive anti-CTLA-4 monoclonal antibody designed to preserve CTLA-4 recycling while preferentially depleting immunosuppressive T cells within tumors. Co-developed with BioNTech for treatment of immunotherapy-resistant non-small cell lung cancer and other advanced tumors; demonstrated 54% reduction in death risk (HR 0.46) versus standard chemotherapy in Phase 3 squamous NSCLC.
  • ONC-841 A therapeutic candidate being developed for solid tumors and Alzheimer's disease, currently in Phase 1/2 clinical trial for Alzheimer's disease following prior development for oncology indications. The candidate leverages Siglec pathway targeting to restore microglial function.

Quantifiable outcome

  • Gotistobart demonstrated 54% reduction in death risk (HR 0.46) versus standard chemotherapy in Phase 3 trial for squamous NSCLC
  • +1 more outcomes

Companies that use OncoC4

Customer profile

Segments2 records

Ideal customer profiles2 records

OncoC4 technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

OncoC4 partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • BioNTech SEcoreStrategic or Co-development PartnerBioNTech and OncoC4 co-developed gotistobart (BNT316/ONC-392), a pH-sensitive anti-CTLA-4 antibody demonstrating sustained anti-tumor activity and clinically relevant overall survival rates in platinum-resistant ovarian cancer. BioNTech presents clinical data at major conferences including ASCO 2026. Partnership advancing multiple late-stage clinical trials.
  • Bristol Myers SquibbcoreStrategic or Co-development PartnerPartnership for development of pumitamig, an immunomodulator candidate. BioNTech highlighted pumitamig data from ROSETTA Lung-02 trial showing encouraging anti-tumor activity in first-line non-small cell lung cancer. Multiple global Phase 3 studies ongoing.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

OncoC4 competitors and assessment

Company assessment

Direct peers

  • Compugen: Clinical-stage immuno-oncology company developing novel checkpoint-based therapeutics using a computational discovery platform. Comparable to OncoC4 in stage, size, and focus on next-generation immune checkpoint targets for solid tumors.
  • Werewolf Therapeutics: Clinical-stage biotech developing conditionally activated immuno-oncology therapeutics, including PREDATOR platform-based INDUKINE molecules. Similar size, clinical-stage profile, and IO focus to OncoC4.
  • Shattuck Labs: Clinical-stage immuno-oncology company developing bifunctional fusion proteins and bispecifics targeting TNF superfamily and immune checkpoints. Direct overlap with OncoC4's BsAb modality and checkpoint pipeline.
  • Surface Oncology: Clinical-stage immuno-oncology biotech focused on next-generation antibodies targeting innate and adaptive immune checkpoints. Highly comparable in target space (PVRIG, IL-27) and stage to OncoC4.
  • Pionyr Immunotherapeutics: Clinical-stage immuno-oncology company developing myeloid-targeting antibodies for solid tumors. Overlaps with OncoC4's innate immune checkpoint approach (e.g., Siglec, CD24 targeting) and clinical-stage profile.

Broad incumbents

  • Bristol Myers Squibb: Global pharma with the leading approved anti-CTLA-4 (ipilimumab/Yervoy) and PD-1 (Opdivo) franchises. OncoC4's BMS partnership for pumitamig plus its CTLA-4 ambitions place BMS as both partner and principal incumbent competitor.
  • Merck & Co. Owns Keytruda (pembrolizumab), the dominant PD-1 checkpoint inhibitor against which OncoC4's PD-1/VEGF program will compete. Represents the standard-of-care benchmark for OncoC4's IO development.
  • Roche: Major IO player with Tecentriq (anti-PD-L1) and broad bispecific antibody pipeline. Comparable commercial and development scope to OncoC4's IO ambitions across multiple checkpoint targets.
  • AstraZeneca: Owns Imfinzi (anti-PD-L1) and tremelimumab (anti-CTLA-4), the most direct approved competitor to gotistobart. Comparable dual-checkpoint strategy (PD-1/VEGF parallels Imfinzi+tremelimumab combinations).

Regional players

  • Innovent Biologics: Leading Chinese biopharma with marketed PD-1 inhibitor (sintilimab) and broad oncology biologics pipeline including bispecifics. Comparable to OncoC4 in bispecific antibody development and Chinese clinical footprint via OncoC4's Nanjing/Guangzhou/Beijing subsidiaries.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

OncoC4 social profiles

Digital presence

OncoC4 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OncoC4 leadership team

Management profile

Number of profiles

Profiles4 records

OncoC4 subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

OncoC4 funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OncoC4 M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OncoC4

What does OncoC4 do?

OncoC4 discovers and develops novel biological therapeutics targeting innate and adaptive immune checkpoints—specifically CTLA-4, PD-1/VEGF, CD24, and Siglec pathways—for hard-to-treat cancers and neurodegenerative diseases such as Alzheimer's. The company leverages proprietary pH-sensitive antibody engineering and multiple modalities including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. Its lead clinical candidate, gotistobart (ONC-392/BNT316), is a pH-sensitive anti-CTLA-4 antibody co-developed with BioNTech, with a second candidate ONC-841 advancing in oncology and Alzheimer's disease indications.

Is OncoC4 a public or private company?

OncoC4 is a private company. It is classified as venture growth investor backed and is currently operating.

When was OncoC4 founded?

OncoC4 was founded in 2020. It employs 51 to 100 people.

Where is OncoC4 based?

OncoC4 is headquartered in Rockville, United States, in the North America region.

How does OncoC4 make money?

One revenue line is on record: pipeline Development and Potential Commercialization.

Who are OncoC4's main competitors?

Direct peers on record are Compugen, Werewolf Therapeutics, Shattuck Labs, Surface Oncology and Pionyr Immunotherapeutics. Broad incumbents are Bristol Myers Squibb, Merck & Co., Roche and AstraZeneca. Innovent Biologics is listed as a regional player.

Does OncoC4 have an API?

No public API is recorded for OncoC4.

What industry is OncoC4 in?

OncoC4's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PRESSBEEOncoC4 Reports Encouraging Phase 1/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026 ...Middle EastOncoC4 reported preliminary Phase 1/2 data for cesalatamig monotherapy in PD-(L)1-resistant/refractory non-small cell lung cancer at SITC 2026. The data showed a 33% investigator-assessed objective response rate and a 90% disease control rate at 10 mg/kg every three weeks, supporting further development.PR NewswireOncoC4 Appoints Dr. Dan Janiak as Chief Business OfficerOncoC4 appointed Dr. Dan Janiak as Chief Business Officer, bringing over 15 years of biotech experience. He previously served as Executive Director of Business Development at AstraZeneca and President and COO of Trotana Therapeutics. The company's pipeline includes oncology and immunology programs, with a strategic collaboration with BioNTech.PR Newswire APACOncoC4 Appoints Dr. Dan Janiak as Chief Business OfficerOncoC4 appointed Dr. Dan Janiak as Chief Business Officer, bringing over 15 years of biotech experience. He previously served as Executive Director of Business Development at AstraZeneca and President and COO of Trotana Therapeutics. He will lead business development and corporate strategy to advance the company's pipeline.PR Newswire APACOncoC4 Receives FDA Fast Track Designation for Cesalatamig, an Investigational PD-1/VEGF Bispecific AntibodyThe FDA granted Fast Track Designation to OncoC4's cesalatamig for NSCLC progressing after PD-(L)1 immunotherapy and platinum chemotherapy. The designation follows Phase 1/2 trials showing safety and efficacy signals. The company plans to advance to registrational Phase 3 development.Clinical Trials ArenaBioNTech and OncoC4 report median OS data from RESERVE-003 Phase III trialBioNTech and OncoC4 reported median overall survival data from the PRESERVE-003 Phase III trial for gotistobart in squamous NSCLC. Gotistobart showed a statistically significant OS benefit over docetaxel, with median OS of 18.5 months versus 10.0 months. The pivotal stage 2 trial is ongoing at over 160 global sites.Quiver QuantitativeBioNTech and OncoC4 Report Updated Phase 3 Data Showing Gotistobart Nearly Doubles Overall Survival in Squamous NSCLC | BNTX Stock NewsBioNTech and OncoC4 reported updated Phase 3 data from the PRESERVE-003 trial of gotistobart in squamous non-small cell lung cancer, showing a median overall survival of 18.5 months versus 10.0 months with standard chemotherapy. The benefit is statistically significant, and the trial continues with a pivotal stage ongoing.FinancialContent Business PageBioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer PatieBioNTech and OncoC4 presented updated data from the PRESERVE-003 Phase 3 trial showing gotistobart's median overall survival of 18.5 months versus 10.0 months with docetaxel in squamous NSCLC patients. The benefit was statistically significant (HR 0.56, p=0.0295) and consistent with the drug's Treg-depleting mechanism. The pivotal stage 2 trial is ongoing at over 160 sites.InvestegateBioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer PatieBioNTech and OncoC4 presented updated data from the PRESERVE-003 Phase 3 trial showing gotistobart nearly doubled median overall survival in previously treated squamous non-small cell lung cancer patients, reaching 18.5 months versus 10.0 months with docetaxel. The data, presented at IASLC 2026, showed a statistically significant benefit with a manageable safety profile.The Pharma LetterGotistobart nearly doubles survival in pretreated squamous lung cancerBioNTech and OncoC4 reported mature overall survival data from the first stage of their Phase III lung cancer trial, showing patients with metastatic squamous NSCLC treated with gotistobart lived a median of 18.5 months versus 10.0 months for those given docetaxel. The figures were presented at the 2026 World Conference on Lung Cancer.PR Newswire APACOncoC4 Appoints Dr. Steve Chen, JD, PhD as General CounselOncoC4 appointed Steve Chen, JD, PhD, as General Counsel. He previously served as General Counsel at HiFiBiO and ENSEM Therapeutics and held legal roles at DSM. He will support corporate governance, IP strategy, and compliance as the company advances its clinical programs.